Things Don't Look Good for This Drug

There's never a sure thing when it comes to decisions from the Food and Drug Administration, but when it comes to Cornerstone Therapeutics' (NAS: CRTX) drug Lixivaptan, investors have all but conceded that a complete response letter (read: rejection) is in the cards.

In the following video, health care bureau chief Brenton Flynn and analyst David Williamson discuss why the outlook is so gloomy for this drug, and how one company is looking particularly smart for cutting ties with the drug two years ago.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article Things Don't Look Good for This Drug originally appeared on

Brenton Flynn and David Williamson have no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Biogen Idec. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.